Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relapsed refractory multiple myeloma

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.19
Views: 1018
Rating:

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France

Prof Xavier Leleu talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the use of carfilzomib, lenalidomide and dexamethasone in the relapsed setting.

He discusses why this weekly treatment regimen is important and more practical instead of being administered twice a week.

He also mentions the advantages associated with this type of treatment, which include improved quality of life and progression-free survival.

Prof Leleu mentions the new phase III trial, AERO-2 which will examine the administration of carfilzomib at 56mg/m² once a week compared to carfilzomib at 27mg/m².

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation